June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Severe Oculocutaneous Manifestations of Monkeypox Infection in the Immunocompromised and Management Considerations
Author Affiliations & Notes
  • Alexi Geevarghese
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Elena Solli
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Steven Carrubba
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Samyuktha Guttha
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Jeffrey Sims
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Laurence Sperber
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Ann Ostrovsky
    Ophthalmology, NYU Langone Health, New York, New York, United States
  • Footnotes
    Commercial Relationships   Alexi Geevarghese None; Elena Solli None; Steven Carrubba None; Samyuktha Guttha None; Jeffrey Sims None; Laurence Sperber None; Ann Ostrovsky None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 146. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alexi Geevarghese, Elena Solli, Steven Carrubba, Samyuktha Guttha, Jeffrey Sims, Laurence Sperber, Ann Ostrovsky; Severe Oculocutaneous Manifestations of Monkeypox Infection in the Immunocompromised and Management Considerations. Invest. Ophthalmol. Vis. Sci. 2023;64(8):146.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cases of human monkeypox (MPX) have been on the rise, and has been declared a global public health emergency since July 2022. The presentation of MPX is variable, and can be especially severe in immunocompromised patients. We present a retrospective case series demonstrating the unusually severe and progressive oculocutaneous manifestations of MPX viral infections in two immunocompromised patients with AIDS, and present some considerations for management.

Methods : Two patients who were treated at Bellevue Hospital NYC Health and Hospitals in 2022 for severe oculocutaneous MPX were included in the study. The clinical presentation, clinical course, and response to treatment are described.

Results : The first case involves a 33 year-old man coinfected with MPX and HIV (CD4 55 cells/µL) who presented with a confluent necrotic facial rash that ultimately led to destruction of the intraocular contents with bilateral globe rupture (figure 1). The second case involves a 45 year-old man coinfected with MPX and HIV (CD4 29 cells/µL) who manifested expansively necrotic skin lesions that evolved into panfacial gangrene involving the bilateral eyelids, rendering the patient unable to open the eyes. Both patients eventually expired as a result of systemic complications from MPX.

Conclusions : It is essential for clinicians to be aware of these potentially severe manifestations of MPX in immunocompromised populations such as those with AIDS. On identification of this severe disease entity, prompt initiation of systemic antiretrovirals, FDA-approved Tecoviromat is recommended. Additional treatment with vaccinia immune globulin, cidofovir, or brincidofovir should also be considered. Early application of topical antivirals with debridement of necrotic tissue may also play a role in management.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Figure 1: CT scan of orbits demonstrating bilateral globe rupture.

Figure 1: CT scan of orbits demonstrating bilateral globe rupture.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×